NEW YORK (GenomeWeb News) – Exact Sciences has licensed exclusive, worldwide rights from OncoMethylome Sciences to DNA methylation biomarkers for use in the stool-based detection of colorectal cancer.
In addition, Madison, Wis.-based Exact Sciences also licensed non-exclusive access to part of OncoMethylome's platform technology. In return, the Belgian firm will receive milestone payments and royalties on net sales
Exact Sciences' primary product, which is currently in development, is a stool-based DNA test for colorectal cancer screening. The agreement with OncoMethylome follows last year's licensing of worldwide rights to Hologic's Invader plus and real-time Invader detection chemistries for colorectal screening applications.
"Our team has developed a new approach to stool-DNA testing that uniquely includes multiple methylation markers in a single assay, and achieves exceptionally high sensitivity and specificity," Exact Sciences President and CEO Kevin Conroy said in a statement. "The inclusion of these markers makes us even more confident about the likelihood of success with our upcoming validation study."
He added that the firm intends to discuss the results of that study on Oct. 29, at the American Association of Cancer Research meeting in Philadelphia.